B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis

Joseph Tuscano, Shiloh Martin, Kyle Song, Theodore Wun

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalHematology
Volume10
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Cell- and Tissue-Based Therapy
Autoimmune Diseases
Rheumatoid Arthritis
B-Lymphocytes
Monoclonal Antibodies
Therapeutics
Poisons
Immune System
Clinical Trials
Technology
Antibodies

ASJC Scopus subject areas

  • Hematology

Cite this

B cell reductive therapy in the treatment of autoimmune diseases : A focus on monoclonal antibody treatment of rheumatoid arthritis. / Tuscano, Joseph; Martin, Shiloh; Song, Kyle; Wun, Theodore.

In: Hematology, Vol. 10, No. 6, 12.2005, p. 521-527.

Research output: Contribution to journalArticle

@article{ae1b87777bdb44d1856a5ef03df983a6,
title = "B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis",
abstract = "The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.",
author = "Joseph Tuscano and Shiloh Martin and Kyle Song and Theodore Wun",
year = "2005",
month = "12",
doi = "10.1080/10245330500155424",
language = "English (US)",
volume = "10",
pages = "521--527",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - B cell reductive therapy in the treatment of autoimmune diseases

T2 - A focus on monoclonal antibody treatment of rheumatoid arthritis

AU - Tuscano, Joseph

AU - Martin, Shiloh

AU - Song, Kyle

AU - Wun, Theodore

PY - 2005/12

Y1 - 2005/12

N2 - The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.

AB - The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.

UR - http://www.scopus.com/inward/record.url?scp=31144454851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144454851&partnerID=8YFLogxK

U2 - 10.1080/10245330500155424

DO - 10.1080/10245330500155424

M3 - Article

C2 - 16321818

AN - SCOPUS:31144454851

VL - 10

SP - 521

EP - 527

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - 6

ER -